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The adipocyte, in addition to functioning as an energy storage cell, is an important 
immune cell that links the innate and adaptive immune system. In obese humans, our 
laboratory has previously demonstrated that the major histocompatibility complex II 
(MHCII) pathway is one of the most differentially expressed between lean and obese 
adipocytes. Further work in high fat diet fed mouse models demonstrates that increased 
adipocyte MHCII expression resulted in pro-inflammatory T cell differentiation leading to 
insulin resistance and decreased glucose tolerance. In contrast, loss of adipocyte MHCII 
expression in aMHCII knockout male mice resulted in less inflammatory adipose tissue 
characterized by increased adipose tissue immunosuppressive regulatory T cells (Tregs) 
and prevented the development of insulin resistance and glucose intolerance induced by 
Western high fat diet (WD).  Moreover, these mice had less atherosclerosis and less liver 
steatosis and inflammation, common complications of obesity. We, thus, aimed to 
understand the impact of the loss of aMHCII expression in female mice on these and 
other inflammatory complications.  
We crossed aMHCII KO mice with proatherogenic low density lipoprotein receptor 
knockout (LDLR-/-) mice, aged the female animals for one year to accelerate 
atherosclerosis and hepatic injury, and fed them WD for twelve weeks (n=12 control, n=12 
aMHCII KO). Glucose (GTT) and insulin (ITT) tolerance tests, body fat composition and 
fasting blood were collected prior to WD start and at study end. At the time of sacrifice, 
visceral adipose tissue was collected for T cell flow analysis and gene expression, liver 
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was collected for liver fat analysis and histology, and aortas were collected for 
atherosclerotic lesion area measurement.   
Results showed that the female aMHCII KO mice experienced a significantly lower 
percent weight gain over 12 weeks than wildtype (control) littermate control mice, despite 
demonstrating no significant difference in overall percent body fat. The knockout mice 
additionally demonstrated improved glucose tolerance after 12 weeks of WD, compared 
to the control mice (AUC control = 23090.0 ± 520.9 vs. KO= 20442.3 ± 657.9, P=0.0045), 
although no difference was observed in insulin sensitivity. No difference was found in 
circulating plasma triglyceride or cholesterol levels; however, liver fat accumulation was 
significantly decreased in KO mice (control= 17.14 ± 0.93 %fat vs. KO= 13.89 ± 1.04 %fat, 
P=0.039). Finally, no difference was found in atherosclerosis % lesion area of the aorta. 
These results support that the adipocyte knockout of MHCII leads to improvement in the 
metabolic and hepatic phenotype in female mice after 12 weeks on WD. However, as the 
females demonstrated some variation from the effects seen in male mice, further 




BACKGROUND AND SIGNIFICANCE 
 
I. Adipocytes and obesity: 
Obesity is a growing epidemic in the United States and worldwide, with over 75% of 
the U.S. adult population currently obese or overweight (Flegal, K.M., et al, 2012; Deng, 
et al, 2016). As the prevalence of obesity increases, so does the burden of its 
comorbidities, including type 2 diabetes mellitus, heart disease, metabolic syndrome, and 
an increased risk of developing certain cancers (Segula, D., 2016). Recent estimates of 
healthcare costs related to obesity exceed $200 billion annually, and costs are continually 
growing (Reynolds, T.H., et al, 2019). Obesity is characterized by both an expansion of 
adipose tissue (AT) and the development of a critical inflammatory state, which mediates 
many of these systemic complications.  
Adipocytes are the cells which comprise the bulk of AT. They function as significant 
long-term energy storage and endocrine cells and have additionally been found to act as 
an important immune cell that links the innate and adaptive immune system (Deng, T., et 
al, 2013). In an environment of caloric excess, adipocytes are uniquely poised to respond 
by storing and releasing excess energy, and by secreting signals that initiate adipose 
inflammation. They also express major histocompatibility complex II (MHCII) molecules, 
which are cell-surface proteins responsible for presenting antigens to CD4+, or helper T 
cells and thus, regulating immune cell behavior (Berry, D.C, 2013).   
Our laboratory has spent considerable time working to characterize the role of MHCII 
expression in AT inflammation and inflammatory-driven complications. In obese humans, 
we have shown that the MHCII pathway is one of the most differentially expressed 
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between lean and obese adipocytes (Deng, T., et al, 2013). MHCII acts as a critical 
determinant of an obesity-induced adipose T cell subset switch 3. As MHCII expression 
is increased in adipocytes, a resulting change is seen in adipose resident T cells to a 
more pro-inflammatory state, characterized by recruitment of more pro-inflammatory 
interferon gamma producing T helper 1 (Th1) cells and fewer anti-inflammatory regulatory 
T (T reg) cells (Deng, T., et al, 2013) in humans. Together, these changes in adipose-
resident T cell quantity and polarization in obesity lead to an increase in inflammation in 
the tissue and act as key determinants of systemic insulin action.  
In high fat diet fed mouse models, we have additionally demonstrated that increased 
adipocyte MHCII expression results in pro-inflammatory T cell differentiation (Deng, T., et 
al, 2017). This switch in subsets of CD4+ T cells in the AT led to insulin resistance and 
decreased glucose tolerance. In contrast, loss of adipocyte MHCII expression in aMHCII 
knockout male mice resulted in less inflammatory adipose tissue, characterized by 
increased adipose tissue immunosuppressive Tregs. The loss of MHCII additionally 
prevented the development of insulin resistance and glucose intolerance induced by high 
fat, high cholesterol Western Diet (WD). Moreover, these mice experienced an 
improvement over controls in the development of fewer inflammatory complications 
(Deng, T., et al, 2017). 
 
II. Inflammatory-driven complications 
The inflammatory state within AT also induces multiple systemic complications, which 
affect over 180 million adults in the United States (American Liver Foundation, 2017; 
United States Census Bureau, 2019). Insulin resistance, which is a major 
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pathophysiologic change associated with type 2 diabetes, and metabolic syndrome has 
been linked with these pro-inflammatory T cell changes (Flegal, K.M., et al., 2007). 
Additionally, AT inflammation has been shown to play a role in the development of 
atherosclerotic plaques and non-alcoholic fatty liver disease (Blaszczak, A., et. al., 2019).  
Atherosclerosis is characterized by an accumulation of lipids in the subendothelial 
space between the endothelium and smooth muscle tissues in the arteries, which 
increases the risk of developing coronary artery disease, heart attack, or heart failure 
(National Heart, Lung, and Blood Institute, 2019). Atherosclerotic plaques form as a result 
of long-term, non-resolving inflammation. It is characterized by a similar CD4+ T cell 
subset switch to an accumulation of pro-inflammatory Th1 cells due to their role in 
oxidative modification of lipids (Blaszczak, A., et. al., 2019). We have found that a 
repletion of anti-inflammatory T regs inhibits plaque progression in atherosclerosis-prone 
mice, confirming their role in attenuating inflammation (Deng, T., et. al. 2013). More recent 
studies have continued to characterize the effect of AT inflammation and immune-cell 
changes in atherosclerosis lesion size and complexity in the aorta (Blaszczak, A., et. al., 
2019). 
Another major complication associated with inflammation and obesity is non-alcoholic 
fatty liver disease (NAFLD). NAFLD is defined as an accumulation of fat in the liver, and 
is the most common liver disease worldwide, affecting nearly all individuals with obesity 
and insulin resistance (American Liver Foundation, 2017).  Proinflammatory cytokines 
similar to those secreted by the adipocyte in obesity are also upregulated in the liver and 
combined with the accumulation of fatty acids, these conditions activate an inflammatory 
cascade (Blaszczak, A., et. al., 2019). 
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Understanding the nature of inflammation, specifically the pathways directed by MHCII 
molecules in the adipose tissue, is therefore vital to developing better therapies to combat 
these systemic inflammatory-driven complications. Current treatment options are limited 
to managing the comorbidities through diet and exercise, and if necessary, through 
management of insulin resistance, hypertension and hypertriglyceridemia (Blaszczak, A., 
et. al., 2019). There is currently no effective treatment for the management of NAFLD, 
which contributes significantly to morbidity and mortality related to obesity. Similarly, 
despite therapies such as statins or LDL reduction, atherosclerosis continues to pose a 
significant risk to obese humans, as progression overtime can lead to the development 
of coronary artery disease (Blaszczak, A., et. al., 2019). The link between AT 
accumulation and inflammation and these complications has recently been determined, 
and thus, the emerging potential for immunologic-based treatment options could be a 
promising route to decrease the impact of these comorbidities in the treatment of obese 
individuals in the future.  
 
III. Previous findings and project aim  
In a novel study, the Hsueh lab generated a mouse model with adipocyte-specific 
MHCII deficiency (aMHCII -/-) and used male aMHCII -/- and wild-type (control) mice to 
explore the role of MHCII upregulation in CD4+ adipose-resident T cell (ART) changes, 
adipose inflammation, and systemic insulin resistance (IR) (Deng, T., et al., 2013). It was 
found that mice with the knockout were protected from diet-induced IR due to the role of 
MHCII expression in adipocyte inflammation.  
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To study the role of MCHII expression on the other inflammatory-driven complications 
of fatty liver disease and atherosclerosis, we developed a pro-atherogenic LDLR-/- mouse 
model with an adipocyte knockout of MHCII (aMHCII -/-, LDLR -/-) (Blaszczak, A., et. al., 
2019). The LDLR -/- mice contain a mutation that affects their low-density lipoprotein 
receptor (LDLR) (Khan, A., et al., 2018), leading to increased plasma levels of cholesterol 
on a normal chow diet, and more severe atherosclerotic lesions and liver fat accumulation 
on high-fat and high-cholesterol diets. It was found that the loss of adipocyte MHCII 
expression in these LDLR -/- aged mice reversed these effects and resulted in a nearly a 
50% reduction in atherosclerosis and liver fat accumulation with no difference in weight 
or body fat accumulation between groups. These reductions in complications were 
associated with a maintenance of AT T regs, as opposed to the drop that typically occurs 
with high fat diet, highlighting a key immune function of the adipocyte in obesity through 
its regulation of AT T cells (Blaszczak, A., et. al., 2019). 
Both of these aforementioned studies, however, were limited to using male mice. In 
order to more fully characterize the MHCII pathway, it is necessary to explore the 
mechanisms of MHCII expression in females.  
Before beginning testing, it was understood that a sex-specific resistance to obesity 
has previously been found in female mice. A study by Jacobs et. al found that female 
LDLR -/- mice responded better to diets that promote atherogenesis and were more 
representative of human adults with cardiovascular disease than the male mice (Jacobs 
S.A.H., et al, 2019). The male models were more susceptible to the detrimental effects of 
high fat diet, resulting in increased adipocyte size, storage, and inflammation, as well as 
an increase in liver fat as compared to the females. In order to fully establish the role of 
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MHCII expression on inflammation and inflammatory-driven complications in our lab, we 
sought to perform testing in female cohorts of mice.  
The objective of this study was to understand the impact of altering the immune 
cell populations in the AT through the inhibition of antigen presentation by MHCII 
on development of atherosclerosis and fatty liver disease in female aged pro-
atherogenic mice. It was hypothesized that the female aged aMHCII -/- LDLR -/- (KO) 
mice on Western diet (WD) will exhibit improved glucose tolerance and insulin sensitivity 
and be better protected from diet-induced CD4+ ART changes, atherosclerosis, and fatty 
liver disease in comparison to the LDLR -/- control mice.   
With a better understanding of how MHCII expression affects systemic inflammatory-
driven complications, the lab hopes to move toward eventually finding potential therapies 






I. Mouse models 
 Previously generated aMHCII -/- mice (AdipoCre, H2Ab1 flox/ flox) were crossed 
with pro-atherogenic low-density lipoprotein receptor knockout (LDLR-/-) mice to 
generate litters of LDLR-/- (control) and aMHCII LDLR-/- (KO) animals. The knockout 
strategy of aMHCII consists of LoxP sites flanking exon1 of H2-Ab1 for its exclusion 
(Deng, T., et al, 2013). LDLR -/- mice were initially obtained from Jackson Laboratory.  
After breeding the animals, PCR genotypic analysis was employed by TransnetYX 
to determine the genotype of the female control and KO mice. The mice were aged for 
one year on standard chow diet to accelerate atherosclerosis development and hepatic 
injury before starting a high fat, high cholesterol diet (Western Diet) at roughly 52 weeks 
of age. All female animals were group housed, kept on a 12-hour light dark cycle and are 
cared for according to animal use and care protocols approved by The Ohio State 
University Institutional Animal Care and Use Committee within pathogen-free animal 
facilities. Sample size for this project was n=12 control, n=12 aMHCII KO mice in total, 
spread across 3 separate cohorts of mice. The first cohort of n=5 and n=3 KO began 
baseline testing in March of 2018; the second of n=2 and n=3 KO began in April of 2018, 
and the third of n=5 and n=6 KO began in October of 2020. Average age at study start 
for all three cohorts were control: 53.3 ± 1.3 weeks vs KO: 51.7 ± 1.4 weeks, p=0.416. 
At baseline, prior to diet change, animals are assessed for body weight, % body 
fat, insulin and glucose tolerance, and fasting blood draws, which is additionally repeated 
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at study end. Techniques and experimental strategy for these metabolic studies are 
discussed below.  
 
II. Body Composition and Metabolic analyses 
Body mass is measured to 0.1g for each animal at baseline, at the same time of 
day each week while the mice are on WD, and at sacrifice after the completion of the 12 
weeks. The percent body fat measurements are taken with the EchoMRI machine for 
each animal at baseline and 12 weeks of diet. Percent fat total is calculated as a 
percentage of fat detected by the machine over total measured body weight.  
Glucose tolerance and insulin sensitivity is assessed at baseline and at 12 weeks 
of WD through glucose tolerance tests (GTT) and insulin tolerance tests (ITT). For ITTs, 
chow is removed 6 hours prior to test start. The animals are fasted overnight, or 16 hours 
prior to GTTs. In both tests, baseline blood glucose measurements are collected with the 
Contour Next Easy meter and Contour Next blood glucose test strips using tail vein blood 
samples. Blood glucose values are additionally measured 15, 30, 45, 60, 90, and 120 
minutes after intraperitoneal glucose injection (1g/ kg body weight), and 15, 30, 45, 60, 
and 90 minutes after intraperitoneal insulin injection (0.75U/ kg body weight). Normalized 
glucose values and area under the curve data is calculated using Microsoft Excel. A 
student paired-t test of raw measurements and normalized glucose values for the two 
groups of mice provides a measurement of significance of p<0.05. Additionally, consistent 
glucose measurements of a mouse that fall more or less than two standard deviations 
from the mean for the group were considered for exclusion of the individual mouse data 
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from the experiment. Outlying values could occur due to an issue in the injection of insulin 
or glucose, or due to poor general health of the animal.  
For fasting blood draws, animals are fasted for 6 hours prior to a submandibular 
bleed at the right jaw. Blood is collected in EDTA tubes, transferred to ice and immediately 
processed within the lab for plasma isolation. The blood is first spun at 2,000 x g for 10 
minutes, then after centrifugation, the upper plasma layer is transferred to a new tube and 
placed in the -20°C freezer until analysis by ELISA. For each sample, glucose, insulin, 
leptin, triglycerides and cholesterol is quantified in duplicate to ensure accurate 
measurements. Glucose levels are quantified using the Contour Next Easy meter with 
Contour Next blood glucose test strips and then the plasma samples are sent to the 
University of Cincinnati Medical Center Mouse Metabolic Phenotyping Center for insulin, 
cholesterol and triglyceride quantification. Aliquots of plasma are also sent to the 
University of Michigan ULAM In-Vivo Animal Core for quantification of aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) liver enzymes by ELISA.  
Circulating glucose and insulin levels are used to calculate Homeostatic Model 
Assessment of Insulin Resistance (HOMA-IR) for the animals according to the formula: 
fasting insulin (µU/mL) x fasting glucose (mg/dL)/405. A lower HOMA-IR value 
corresponds with increased insulin sensitivity.  
   
III. Aorta Dissection and Sudan IV Staining  
 To begin atherosclerosis analysis, the aortas are pulled from the sacrificed animals 
and flushed with 10ml of phosphate buffered saline (PBS) and then dissected en-bloc 
from the heart to the iliac bifurcation. External fat and connective tissues are removed 
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through cutting and pulling with dissection instruments, and then the cleaned aortas are 
placed in 10% phosphate buffered formalin for at least 24 hours before transferring to 
70% ethanol. The full aorta tissues are then cut along the midline to open the aorta, and 
they are pinned to a silicone tray with 0.2mm insect pins.  
Aortas are stained with Sudan IV solution (consisting of 0.5% Sudan IV wt/v, 35% 
ethanol/50% acetone) for 15-30 minutes at room temperature with continuous shaking. If 
necessary, 70% ethanol is used to de-stain Sudan IV particles from the aorta with 
continuous shaking to ensure a clear stain. Plaques appear pink, as the Sudan IV stains 
for lipids and triglycerides. Next, aortas are imaged using a dissecting microscope. Using 
ImageJ software, the total area of the aorta and lesions are each traced, then the 
measured % area of lesion coverage by atherosclerotic plaques is calculated for the arch 
portion and whole aorta. After all images are captured and analyzed, the aortas are 
washed in 80% ethanol until destained. 
 
IV. Liver Fat Analysis 
 Liver fat accumulation is assessed in the mice using a portion of the liver isolated 
at the sacrifice of the animals. Livers are removed, and a portion of the right lobe is placed 
on ice until EchoMRI biopsy analysis. Data from the EchoMRI machine is used to 
calculate a fat % total of the liver using the formula: fat (g) / (fat + lean (g)) x 100%.  
Paraffin-wax embedded liver samples are additionally stained with hematoxylin 
and eosin staining and sliced to create tissue slides. Tissue composition and cellular 
structure are visualized and photographed with the Echo Revolve Brightfield microscope.  
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V. Statistical Analysis 
 All data are presented as means ± SEM. Student t-tests were done for all 





I. Body Weight and Percent Body Fat  
We found no differences in body weight or percent body fat between control and 
KO mice, however, when normalized to percent weight gain by mouse, the KO mice 
gained significantly less weight than control littermates. Average body weight at baseline 
showed no differences between control and KO mice (21.8 ± 0.4 g. vs 21.7 ± 0.3 g., 
p=0.939). Additionally, no difference was seen in average body weight at 12 weeks of 
WD between groups (30.0 ± 1.2 g. vs 27.8 ± 0.9 g., p=0.140). Percent weight gain over 
12 weeks of WD was significantly lower for KO mice (37.7 ± 4.0% vs 27.6 ± 2.8%, 
p=0.049). (n=12 control, 12 KO mice). Percent body fat showed no differences at baseline 
(12.15 ± 1.09% vs 12.42 ± 2.27%, p=0.935; n= 2 control, 3 KO), or at 12 weeks (32.49 ± 





Figure 1: Percent Weight gain and body fat composition after 12 weeks 
WD. A) KO females gained significantly less weight after 12 weeks of WD, 
however, B) % body fat showed no differences. (n= 12 control, 12 KO).  
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II. Glucose Tolerance and Insulin Tolerance Testing (GTT and ITT) 
 In order to measure degree of insulin resistance and impaired glucose tolerance, 
baseline and 12-week GTTs and ITTs were conducted. Baseline date showed no 
significant differences between groups in glucose tolerance or insulin sensitivity. In 
performing baseline ITTs, the mice were given insulin doses of 0.50 U/ kg body weight, 
as opposed to the 0.75U/ kg body weight dose due to relatively low starting weights of 
the mice and the desire to avoid hypoglycemic events in the mice during baseline testing.  
 At 12 weeks of WD, repeated GTTs showed an improvement in glucose tolerance 
for the KO animals. The curve of blood glucose values over time showed a significant 
improvement at most time points, additionally, average area under the curve (AUC) 
calculations showed a dramatic improvement over the wild-type controls (23090.0 ± 520.9 
vs 20442.3 ± 0657.9, p=0.0045). Results are shown in Figure 2 below.  
  
 
Figure 2: 12-week glucose tolerance test and average AUC data. 
A) KO mice demonstrate improved glucose tolerance in 12-week GTT 
curve of blood glucose values, with significant improvements at 0, 15, 
30, 60, and 90 minute time points, and trending significance at 30 and 
120 minutes. B) Area under the curve data also showed dramatic 
improvements. (n=12 control, 12 KO).  
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ITTs were additionally repeated at 12 weeks WD, however, at this time, the mice 
received the higher dose (0.75U/ kg body weight) of insulin, as they weighed significantly 
more at 12 weeks on WD than at baseline. Results showed no significant difference 
between control and KO groups, especially when glucose values were normalized to % 
initial curve and % initial average AUC (% initial AUC: 4872.9 ± 308 vs 4444.2 ± 193, 
p=0.251). n= 12 control, and 12 KO animals were tested in each metabolic test with no 




III. Plasma analysis 
Baseline fasting blood draws and plasma analysis was performed for n=6 control, 
and 7 KO animals. No differences could be observed in circulating glucose, triglyceride, 
or cholesterol at study start. Due to a mix-up at the testing facility, insulin levels were not 
measured at baseline, however levels of circulating leptin were measured and additionally 
Figure 3: 12-week insulin tolerance test and average AUC data. 
A) No differences were observed in 12-week ITT curve of % initial 
blood glucose value at any time point. B) %initial area under the curve 
data also showed no difference in insulin sensitivity between groups. 
(n=12 control, 12 KO).  
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showed no difference between groups. Without insulin data, HOMA-IR could not be 
calculated. Finally, samples were not sent for measurement of ALT or AST enzyme levels 
at baseline.  
At 12 weeks of WD, fasting blood draws were performed on the same cohorts of 
animals, and the plasmas were analyzed for glucose, insulin, leptin, triglyceride, 
cholesterol, ALT and AST enzyme levels. No differences were observed in any of the 
measurements, including HOMA-IR calculation, as illustrated in Figure 4 below.  
 
 
Figure 4: Circulating plasma 
levels of. A). glucose, 
triglycerides, cholesterol, liver 
AST and ALT enzymes, and 
B) insulin, and HOMA-IR 
show no differences between 
groups after 12 weeks on WD 
(n=7 control, 6 KO). 
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IV. Liver Fat Accumulation  
 EchoMRI tissue percent fat analysis of liver segments taken from female mice at 
sack showed that liver fat accumulation was significantly decreased in KO animals (17.1 
± 0.9% vs 13.9 ± 1.0%, p=0.0390; Figure 5). Representative H&E-stained slides of 
control and KO animals visually show smaller fat droplets in KO mice, as illustrated below.  
 
 
V. Atherosclerotic Lesion Area 
 Analysis of atherosclerotic lesion area of the aorta showed no differences in % 
lesion coverage in the aortic arch (16.9 ± 3.7% vs 15.7 ± 4.0%, p=0.826), or the whole 
aorta (10.6 ± 1.9% vs 10.4 ± 2.8%, p=0.934). Representative images of Sudan IV-stained 
aortas additionally show no dramatic visual differences in lesion area coverage. Results 
of atherosclerosis analysis are depicted below in Figure 6.  
Figure 5: Liver fat accumulation after 12 weeks on WD. Liver 
fat accumulation was significantly decreased in KO females 












Figure 6: Atherosclerotic lesion area measurement of the 
dissected aortas. No significant difference was observed in 
atherosclerotic lesion area of the arch or whole aorta following 




Adipocyte MHCII expression in obesity is a critical determinant of systemic 
metabolic health. Investigation of the adipocyte MHCII pathway has repeatedly supported 
the role of the pathway in obese adipocytes in directly activating T cells and influencing 
adaptive immunity and adipose inflammation. Adaptive immunity, we’ve found, plays a 
significant role in the progression of obesity-induced adipose inflammation and insulin 
resistance, and more recent work has also illustrated the role of MHCII expression in 
inciting common inflammatory complications of atherosclerosis and liver fat accumulation 
(Deng, T., et al., 2013). 
Historically, research into biological processes have largely overlooked the impact 
of sex. Numerous systematic reviews of animal research studies investigating biological 
processes have consistently found a significant overrepresentation of male mice in 
studies, and an even more significant lack of analysis of sex differences when both 
genders were employed (Beery A.K., 2010). The instance of sex differences is not limited 
to mice, however, as many known human disease processes vary widely by gender. 
These findings have led to a growing concern over the sex imbalances in research, as 
well as a concern for the poor generalizability of results in these research studies limited 
to males (Ingvorsen, C, et al., 2017).  
The current investigation aimed to further explore whether inhibiting antigen 
presentation in the adipocytes, and thus, altering the immune cell subsets in the AT, would 
lead to a reduction in atherosclerosis and liver fat accumulation in female pro-atherogenic 
mice. Furthermore, as metabolic health of insulin and glucose tolerance has yet to be 
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assessed in female mice in the lab, it was important to characterize these effects of 
adipose inflammation in the females as well and assess any sex differences that 
emerged.  
Our work in the females has confirmed that the loss of adipocyte MHCII leads to 
improvements in the metabolic and hepatic phenotype, similar to the male counterparts. 
Male pro-atherogenic mice with an adipocyte-specific knockout of MHCII saw improved 
metabolic health characterized by a dramatic decrease in atherosclerotic plaques and 
liver fat accumulation after 12 weeks on WD. Despite similar levels of weight gain and 
body fat accumulation between control and KO mice, the male mice displayed 
improvements in insulin resistance, as well as a nearly 50% reduction in both 
atherosclerosis development and liver fat accumulation (Blaszczak, A., et. al., 2019). 
The male mice also consistently weighed more than the females, beginning at 
baseline testing and persisting throughout the testing period. However, the females and 
males had similar percent weight gain over the 12 weeks on WD, and additionally saw no 
differences in percent body fat at baseline or 12-week assessment. Body weight is a 
significant factor in impaired glucose tolerance and is strongly correlated with poor 
metabolic health, thus posing a significant confounding variable to the sex-driven 
differences (Ingvorsen, C, et al., 2017). Furthermore, studies have shown that total body 
fat, as opposed to percent composition or change might be the biggest driver of insulin 
resistance (Ingvorsen, C, et al., 2017). Other research has additionally shown that male 
LDLR -/- mice are more susceptible to developing larger and more inflamed adipocytes, 
which was in line with our findings (Reynolds, T.H., et al., 2019).  
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Regarding the effects of inflammation, past studies have also noted that female 
mice are generally more resistant to inflammation in response to diet-induced obesity 
(Pettersson U. S., et al., 2012). We found that the male mice trended or performed worse 
during GTT and ITT testing at baseline and 12 weeks than the females. However, within 
each gender, male KO mice saw improved insulin sensitivity to male controls, whereas 
female KO mice only saw an improvement in glucose sensitivity after 12 weeks on WD. 
It has been previously noted that male mice develop more pronounced systemic 
inflammation and insulin resistance than females, which have demonstrated a greater 
ability to expand the T reg population in the AT to counteract the pro-inflammatory 
cascade (Pettersson U. S., et al., 2012). In our testing, we found that circulating insulin 
levels were higher in control males than females, which has also been previously noted 
in studies of high fat diet-fed mice (Ingvorsen, C, et al., 2017).  
Looking at the inflammatory complications of atherosclerosis development and 
liver fat accumulation, the females were generally affected by a lesser degree. Whereas 
female KO mice experienced an improvement in their hepatic phenotype, no difference 
was observed in the atherosclerotic lesion area between female groups. The male KO 
mice, in contrast, saw a nearly 50% reduction in both atherosclerosis and liver fat 
accumulation. Additionally, no differences were observed in circulating plasma 
triglyceride or cholesterol levels within each gender, however, males had significantly 
higher cholesterol levels within the KO mice than females, and increased triglycerides in 
both groups at baseline. Interestingly enough, however, when % liver fat data was 
compared across genders, the female KO animals actually had a greater average % liver 
fat than their male KO counterparts. In looking at plasma levels of ALT and AST liver 
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enzymes, no sex differences were seen, indicating no difference in these markers of liver 
damage. Liver fat accumulation is linked with obesity, insulin resistance, and elevated 
circulating triglycerides. Thus, further characterization of gene and cytokine expression in 
the liver may provide additional explanation to the higher % liver fat in female KO mice. 
It is additionally important to discuss estrogen, which has been historically been a 
cause to exclude female mice from testing. At over a year of age, it is likely that our mice 
are beyond the known onset of menopause in mice, which occurs around 8 months 
(Reynolds, T.H., et al., 2019). Although estrogen can protect female mice from diet-
induced obesity, our models were likely deficient in estrogen. The presence of estrogen 
can also decrease food consumption and promote energy expenditure to prevent obesity 
by creating a negative energy balance. One study found that removing the ovaries, and 
thus removing estrogen production from female ovariectomized mice no longer protected 
the females from obesity and restored their weight-gain pattern to that of the males 
(Stubbins, Renee E., et al., 2011). As we did not assess estrogen levels in our study, the 
potential for estrogen to influence our results is unknown and remains an important factor 
to consider in the future.  
In summary, the current study continued to support the role of adipocyte MHCII 
expression in inciting AT inflammation, impaired glucose tolerance, an abnormal 
accumulation liver fat. As the female mice differed from the males in body mass, insulin 
sensitivity, glucose tolerance, and atherosclerosis lesions, our data supports the 
existence of sex differences in the development of inflammatory-driven complications and 
necessitates the consideration of both genders in metabolic studies moving forward. 
Better understanding the effect of MHCII expression on systemic inflammatory-driven 
 27 
complications across genders paves a way to identifying potential therapies to prevent 
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